1. A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Issue 2 (November 2018) Authors: Panje, Cedric M.; Dedes, Konstantin J.; Matter-Walstra, Klazien; Schwenkglenks, Matthias; Gautschi, Oliver; Siano, Marco; Aebersold, Daniel M.; Plasswilm, Ludwig; Lupatsch, Judith E. Journal: Radiotherapy and oncology Issue: Volume 129:Issue 2(2018) Page Start: 257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Cost‐Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD‐L1 Testing. Issue 11 (November 2016) Authors: Matter‐Walstra, Klazien; Schwenkglenks, Matthias; Aebi, Stefan; Dedes, Konstantin; Diebold, Joachim; Pietrini, Mario; Klingbiel, Dirk; von Moos, Roger; Gautschi, Oliver Journal: Journal of thoracic oncology Issue: Volume 11:Issue 11(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial. (July 2022) Authors: Banna, Giuseppe Luigi; Addeo, Alfredo; Zygoura, Panagiota; Tsourti, Zoi; Popat, Sanjay; Curioni-Fontecedro, Alessandra; Nadal, Ernest; Shah, Riyaz; Pope, Anthony; Fisher, Patricia; Spicer, James; Roy, Amy; Gilligan, David; Gautschi, Oliver; Janthur, Wolf-Dieter; López-Castro, Rafael; Roschitzki-V... Journal: Lung cancer Issue: Volume 169(2022) Page Start: 77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Advances in the treatment of RET-fusion-positive lung cancer. (June 2021) Authors: Pall, Georg; Gautschi, Oliver Journal: Lung cancer Issue: Volume 156(2021) Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. (March 2019) Authors: Lai, W. Victoria; Lebas, Louisiane; Barnes, Tristan A.; Milia, Julie; Ni, Ai; Gautschi, Oliver; Peters, Solange; Ferrara, Roberto; Plodkowski, Andrew J.; Kavanagh, John; Sabari, Joshua K.; Clarke, Stephen J.; Pavlakis, Nick; Drilon, Alexander; Rudin, Charles M.; Arcila, Maria E.; Leighl, Natasha ... Journal: European journal of cancer Issue: Volume 109(2019) Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. (June 2021) Authors: Froesch, Patrizia; Mark, Michael; Rothschild, Sacha I.; Li, Qiyu; Godar, Gilles; Rusterholz, Corinne; Oppliger Leibundgut, Elisabeth; Schmid, Sabine; Colombo, Ilaria; Metaxas, Yannis; König, David; Sessa, Cristiana; Gautschi, Oliver; Früh, Martin Journal: Lung cancer Issue: Volume 156(2021) Page Start: 91 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Issue 7 (July 2017) Authors: Shaw, Alice T; Kim, Tae Min; Crinò, Lucio; Gridelli, Cesare; Kiura, Katsuyuki; Liu, Geoffrey; Novello, Silvia; Bearz, Alessandra; Gautschi, Oliver; Mok, Tony; Nishio, Makoto; Scagliotti, Giorgio; Spigel, David R; Deudon, Stéphanie; Zheng, Cheng; Pantano, Serafino; Urban, Patrick; Massacesi, Crist... Journal: Lancet oncology Issue: Volume 18:Issue 7(2017:Jul.) Page Start: 874 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Clinicopathological Characteristics ofRETRearranged Lung Cancer in European Patients. Issue 1 (January 2016) Authors: Michels, Sebastian; Scheel, Andreas Hans; Scheffler, Matthias; Schultheis, Anne Maria; Gautschi, Oliver; Aebersold, Franziska; Diebold, Joachim; Pall, Georg; Rothschild, Sacha; Bubendorf, Lukas; Hartmann, Wolfgang; Heukamp, Lukas; Schildhaus, Hans‐Ulrich; Fassunke, Jana; Ihle, Michaela Angelika; ... Journal: Journal of thoracic oncology Issue: Volume 11:Issue 1(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology. (February 2014) Authors: Stutz, Emanuel; Gautschi, Oliver; Fey, Martin F; Gugger, Mathias; Tschan, Mario P; Rothschild, Sacha I Journal: Future oncology Issue: Volume 10:Number 2(2014) Page Start: 211 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Issue 5 (May 2017) Authors: Rosell, Rafael; Dafni, Urania; Felip, Enriqueta; Curioni-Fontecedro, Alessandra; Gautschi, Oliver; Peters, Solange; Massutí, Bartomeu; Palmero, Ramon; Aix, Santiago Ponce; Carcereny, Enric; Früh, Martin; Pless, Miklos; Popat, Sanjay; Kotsakis, Athanasios; Cuffe, Sinead; Bidoli, Paolo; Favaretto, ... Journal: Lancet Issue: Volume 5:Issue 5(2017) Page Start: 435 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗